

# PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT												
NATURE OF CONVEYANCE:	ASSIGNMENT												
<b>CONVEYING PARTY DATA</b>													
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;">Name</th> <th style="width: 30%;">Execution Date</th> </tr> </thead> <tbody> <tr> <td>Weilan Ye</td> <td>05/05/2010</td> </tr> <tr> <td>Mark Dennis</td> <td>05/03/2010</td> </tr> <tr> <td>Jill Fredrickson</td> <td>05/05/2010</td> </tr> </tbody> </table>		Name	Execution Date	Weilan Ye	05/05/2010	Mark Dennis	05/03/2010	Jill Fredrickson	05/05/2010				
Name	Execution Date												
Weilan Ye	05/05/2010												
Mark Dennis	05/03/2010												
Jill Fredrickson	05/05/2010												
<b>RECEIVING PARTY DATA</b>													
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;">Name:</td> <td>Genentech, Inc.</td> </tr> <tr> <td>Street Address:</td> <td>1 DNA Way</td> </tr> <tr> <td>Internal Address:</td> <td>MS-49</td> </tr> <tr> <td>City:</td> <td>South San Francisco</td> </tr> <tr> <td>State/Country:</td> <td>CALIFORNIA</td> </tr> <tr> <td>Postal Code:</td> <td>94080</td> </tr> </table>		Name:	Genentech, Inc.	Street Address:	1 DNA Way	Internal Address:	MS-49	City:	South San Francisco	State/Country:	CALIFORNIA	Postal Code:	94080
Name:	Genentech, Inc.												
Street Address:	1 DNA Way												
Internal Address:	MS-49												
City:	South San Francisco												
State/Country:	CALIFORNIA												
Postal Code:	94080												
PROPERTY NUMBERS Total: 1													
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;">Property Type</th> <th style="width: 70%;">Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>12776259</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	12776259								
Property Type	Number												
Application Number:	12776259												
<b>CORRESPONDENCE DATA</b>													
Fax Number: (650)952-9881 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> Phone: 650 467-2607 Email: pgolden@gene.com Correspondent Name: Grant Kalinowski Address Line 1: 1 DNA Way Address Line 2: MS-49 Address Line 4: South San Francisco, CALIFORNIA 94080													
ATTORNEY DOCKET NUMBER:	P4328R1												
NAME OF SUBMITTER:	Grant Kalinowski												
Total Attachments: 6													

CH \$40.00 12776259

**501183514**

**PATENT**  
**REEL: 024422 FRAME: 0744**

source=P4328R1USAssignment#page1.tif  
source=P4328R1USAssignment#page2.tif  
source=P4328R1USAssignment#page3.tif  
source=P4328R1USAssignment#page4.tif  
source=P4328R1USAssignment#page5.tif  
source=P4328R1USAssignment#page6.tif

# A S S I G N M E N T

WHEREAS, Weilan Ye, a citizen of US, residing at 119 Barkentine Street, Foster City, CA 94404, and Mark Dennis, a citizen of US, residing at 120 Plymouth Avenue, San Carlos, CA 94070, and Jill Fredrickson, a citizen of US, residing at 786 Allison Way, Sunnyvale, CA 94087 (hereinafter "ASSIGNORS"), have invented a new and useful invention in

## HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME

for which a provisional application Serial No. 61/176,817 (Docket No. PR4328) has been filed on 8 May 2009; and for which non-provisional application Serial No. 12/776,259<sup>1</sup> (Docket No. P4328R1 US) for Letters Patent has been filed by them on 7 May 2010<sup>1</sup>; and International Application No. PCT/US2010/34097 (Docket No. P4328R1 WO) has been filed by them on 7 May 2010<sup>1</sup>;

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNORS have and do hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNORS covenant and agree to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNORS, their respective heirs, legal representatives and assigns.


Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

<sup>1</sup>Assignors hereby authorize Genentech, Inc., and their representatives and assigns to insert the application numbers and filing date information when they become known.

IN WITNESS WHEREOF we undersign as follows;

South San Francisco

Dated: 5/5/2010

  
\_\_\_\_\_  
Weilan Ye

South San Francisco

Dated: \_\_\_\_\_

\_\_\_\_\_  
Mark Dennis

South San Francisco

Dated: \_\_\_\_\_

\_\_\_\_\_  
Jill Fredrickson

# **ASSIGNMENT**

WHEREAS, Weilan Ye, a citizen of US, residing at 119 Barkentine Street, Foster City, CA 94404, and Mark Dennis, a citizen of US, residing at 120 Plymouth Avenue, San Carlos, CA 94070, and Jill Fredrickson, a citizen of US, residing at 786 Allison Way, Sunnyvale, CA 94087 (hereinafter "ASSIGNORS"), have invented a new and useful invention in

## **HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME**

for which a provisional application Serial No. 61/176,817 (Docket No. PR4328) has been filed on 8 May 2009; and for which non-provisional application Serial No. 12/776,259<sup>1</sup> (Docket No. P4328R1 US) for Letters Patent has been filed by them on 7 May 2010<sup>1</sup>; and International Application No. PCT/US2010/34097 (Docket No. P4328R1 WO) has been filed by them on 7 May 2010<sup>1</sup>;

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNORS have and do hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNORS covenant and agree to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNORS, their respective heirs, legal representatives and assigns.

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

<sup>1</sup>Assignors hereby authorize Genentech, Inc., and their representatives and assigns to insert the application numbers and filing date information when they become known.

IN WITNESS WHEREOF we undersign as follows;


South San Francisco

Dated: \_\_\_\_\_

\_\_\_\_\_  
Weilan Ye

South San Francisco

Dated: 5-3-10

  
\_\_\_\_\_  
Mark Dennis

South San Francisco

Dated: \_\_\_\_\_

\_\_\_\_\_  
Jill Fredrickson

# A S S I G N M E N T

WHEREAS, Weilan Ye, a citizen of US, residing at 119 Barkentine Street, Foster City, CA 94404, and Mark Dennis, a citizen of US, residing at 120 Plymouth Avenue, San Carlos, CA 94070, and Jill Fredrickson, a citizen of US, residing at 786 Allison Way, Sunnyvale, CA 94087 (hereinafter "ASSIGNORS"), have invented a new and useful invention in

## HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME

for which a provisional application Serial No. 61/176,817 (Docket No. PR4328) has been filed on 8 May 2009; and for which non-provisional application Serial No. 12/776,259<sup>1</sup> (Docket No. P4328R1 US) for Letters Patent has been filed by them on 7 May 2010<sup>1</sup>; and International Application No. PCT/US2010/34097 (Docket No. P4328R1 WO) has been filed by them on 7 May 2010<sup>1</sup>;

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNORS have and do hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNORS covenant and agree to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNORS, their respective heirs, legal representatives and assigns.

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

<sup>1</sup>Assignors hereby authorize Genentech, Inc., and their representatives and assigns to insert the application numbers and filing date information when they become known.

IN WITNESS WHEREOF we undersign as follows;

South San Francisco

Dated: \_\_\_\_\_

\_\_\_\_\_  
Weilan Ye

South San Francisco

Dated: \_\_\_\_\_

\_\_\_\_\_  
Mark Dennis

South San Francisco

Dated: May 5, 2010

  
Jill Fredrickson